FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060225329> ?p ?o ?g. }

• W2060225329 endingPage "74" @default.
• W2060225329 startingPage "67" @default.
• W2060225329 abstract "The collective experience with ceftazidime in the treatment of skin, soft tissue, bone, and joint infections is presented. Patients were treated with dosages ranging between 25 and 150 mg/kg per day for between five and 42 days. A total of 570 patients with skin and skin structure infections were treated with ceftazidime. Comparative studies, using either cefamandole or tobramycin plus ticarcillin as control drugs, included 239 patients. There were 600 evaluable patients in five categories of skin or skin structure infection: 252 patients had cellulitis, 107 had wound infections, 103 had abscesses, 90 had skin ulcers, and 48 had other miscellaneous infections. Bacteriologic etiologies were gram-negative rods in 303 episodes, gram-positive cocci in 241, anaerobes in 14 episodes, and miscellaneous other organisms in 48 episodes. Overall bacteriologic efficacy was 90 percent in ceftazidime-treated infections and 76 percent in control-treated infections. The clinical efficacy of ceftazidime against infections caused by the gram-positive cocci, particularly Staphylococcus species, was surprisingly good (85 percent) and similar to the efficacy achieved in the cefamandole-treated patients (85 percent). The overall clinical efficacy for ceftazidime was 93 percent. One hundred thirty-four patients with bone or joint infections received ceftazidime. The dosages were similar, but the duration of treatment was the longest in this group. Ceftazidime treatment was compared with standard dosages of tobramycin and ticarcillin in 11 patients. Osteomyelitis was cured in 58 of the 101 patients who received ceftazidime. In five patients, osteomyelitis failed to respond: in two, a resistant Pseudomonas strain emerged; the other three failures were due to persistent bone sequestra. Thirty-eight patients showed improvement. Of those in the tobramycin and ticarcillin group, nine of 10 evaluable patients (90 percent) showed either cure or improvement. The one failure was due to a persistent sequestrum. Thirteen patients with septic arthritis and seven with bursitis were also treated with ceftazidlme; the overall cure rate was 75 percent. Adverse reactions to ceftazidime were severe, and the drug was discontinued in 13 of 570 (2.3 percent) patients with skin or skin structure infections and in five of 134 (3.7 percent) patients with bone and joint infections. These data suggest that ceftazidime Is effective as monotherapy in the treatment of skin, skin structure, bone, and joint infections, and that it may be more efficacious against staphylococcal infections than predicted from in vitro data." @default.
• W2060225329 created "2016-06-24" @default.
• W2060225329 creator A5067655266 @default.
• W2060225329 date "1985-08-01" @default.
• W2060225329 modified "2023-09-28" @default.
• W2060225329 title "Treatment of skin, skin structure, bone, and joint infections with ceftazidime" @default.
• W2060225329 cites W1488653044 @default.
• W2060225329 cites W1544944539 @default.
• W2060225329 cites W1648103623 @default.
• W2060225329 cites W1974902377 @default.
• W2060225329 cites W1979913528 @default.
• W2060225329 cites W2033162678 @default.
• W2060225329 cites W2059699099 @default.
• W2060225329 cites W2065968621 @default.
• W2060225329 cites W2113823888 @default.
• W2060225329 cites W2149459840 @default.
• W2060225329 cites W2170031325 @default.
• W2060225329 doi "https://doi.org/10.1016/0002-9343(85)90264-5" @default.
• W2060225329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3895921" @default.
• W2060225329 hasPublicationYear "1985" @default.
• W2060225329 type Work @default.
• W2060225329 sameAs 2060225329 @default.
• W2060225329 citedByCount "28" @default.
• W2060225329 countsByYear W20602253292012 @default.
• W2060225329 countsByYear W20602253292014 @default.
• W2060225329 countsByYear W20602253292019 @default.
• W2060225329 crossrefType "journal-article" @default.
• W2060225329 hasAuthorship W2060225329A5067655266 @default.
• W2060225329 hasConcept C126322002 @default.
• W2060225329 hasConcept C141071460 @default.
• W2060225329 hasConcept C162156334 @default.
• W2060225329 hasConcept C2775832221 @default.
• W2060225329 hasConcept C2776083883 @default.
• W2060225329 hasConcept C2776968632 @default.
• W2060225329 hasConcept C2777637488 @default.
• W2060225329 hasConcept C2778974779 @default.
• W2060225329 hasConcept C2780551157 @default.
• W2060225329 hasConcept C501593827 @default.
• W2060225329 hasConcept C523546767 @default.
• W2060225329 hasConcept C54355233 @default.
• W2060225329 hasConcept C71924100 @default.
• W2060225329 hasConcept C86803240 @default.
• W2060225329 hasConcept C89423630 @default.
• W2060225329 hasConceptScore W2060225329C126322002 @default.
• W2060225329 hasConceptScore W2060225329C141071460 @default.
• W2060225329 hasConceptScore W2060225329C162156334 @default.
• W2060225329 hasConceptScore W2060225329C2775832221 @default.
• W2060225329 hasConceptScore W2060225329C2776083883 @default.
• W2060225329 hasConceptScore W2060225329C2776968632 @default.
• W2060225329 hasConceptScore W2060225329C2777637488 @default.
• W2060225329 hasConceptScore W2060225329C2778974779 @default.
• W2060225329 hasConceptScore W2060225329C2780551157 @default.
• W2060225329 hasConceptScore W2060225329C501593827 @default.
• W2060225329 hasConceptScore W2060225329C523546767 @default.
• W2060225329 hasConceptScore W2060225329C54355233 @default.
• W2060225329 hasConceptScore W2060225329C71924100 @default.
• W2060225329 hasConceptScore W2060225329C86803240 @default.
• W2060225329 hasConceptScore W2060225329C89423630 @default.
• W2060225329 hasIssue "2" @default.
• W2060225329 hasLocation W20602253291 @default.
• W2060225329 hasLocation W20602253292 @default.
• W2060225329 hasOpenAccess W2060225329 @default.
• W2060225329 hasPrimaryLocation W20602253291 @default.
• W2060225329 hasRelatedWork W196422572 @default.
• W2060225329 hasRelatedWork W1975973381 @default.
• W2060225329 hasRelatedWork W2044482094 @default.
• W2060225329 hasRelatedWork W2062377102 @default.
• W2060225329 hasRelatedWork W2063374918 @default.
• W2060225329 hasRelatedWork W2140477962 @default.
• W2060225329 hasRelatedWork W2168465173 @default.
• W2060225329 hasRelatedWork W2431077161 @default.
• W2060225329 hasRelatedWork W4206085505 @default.
• W2060225329 hasRelatedWork W4242976680 @default.
• W2060225329 hasVolume "79" @default.
• W2060225329 isParatext "false" @default.
• W2060225329 isRetracted "false" @default.
• W2060225329 magId "2060225329" @default.
• W2060225329 workType "article" @default.